Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer

Activation of MAPK signaling via BRAF mutations may limit the activity of EGFR inhibitors in EGFR-mutant lung cancer patients. However, the impact of BRAF mutations on the selection and fitness of emerging resistant clones during anti-EGFR therapy remains elusive. We tracked the evolution of subclon...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaufler, Diana, Ast, David F., Tumbrink, Hannah L., Abedpour, Nima, Maas, Lukas, Schwäbe, Ayla E., Spille, Inga, Lennartz, Stefanie, Fassunke, Jana, Aldea, Mihaela, Besse, Benjamin, Planchard, David, Nogova, Lucia, Michels, Sebastian, Kobe, Carsten, Persigehl, Thorsten, Westphal, Theresa, Koleczko, Sophia, Fischer, Rieke, Weber, Jan-Phillip, Altmüller, Janine, Thomas, Roman K., Merkelbach-Bruse, Sabine, Gautschi, Oliver, Mezquita, Laura, Büttner, Reinhard, Wolf, Jürgen, Peifer, Martin, Brägelmann, Johannes, Scheffler, Matthias, Sos, Martin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683498/
https://www.ncbi.nlm.nih.gov/pubmed/34921211
http://dx.doi.org/10.1038/s41698-021-00241-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683498/
https://www.ncbi.nlm.nih.gov/pubmed/34921211
http://dx.doi.org/10.1038/s41698-021-00241-9

Ejemplares similares